|1.||Langer, Martin: 4 articles (01/2005 - 08/2002)|
|2.||Müthing, Johannes: 3 articles (08/2008 - 08/2002)|
|3.||Lentzen, H: 3 articles (07/2005 - 11/2001)|
|4.||Niemeyer, Christof M: 3 articles (04/2004 - 01/2003)|
|5.||Schumacher, Udo: 2 articles (09/2010 - 01/2007)|
|6.||Freudlsperger, Christian: 2 articles (09/2010 - 01/2007)|
|7.||Haier, Jörg: 2 articles (08/2008 - 01/2005)|
|8.||Peter-Katalinic, Jasna: 2 articles (08/2008 - 08/2002)|
|9.||Senninger, Norbert: 2 articles (08/2008 - 01/2005)|
|10.||Bolte, O: 2 articles (07/2005 - 12/2004)|
01/17/2003 - "To allow for pharmacokinetic studies in adjunction with the current clinical developments of the potent cytostatic anti-cancer drug rViscumin, a sandwich immuno-PCR (IPCR) assay was developed for the detection of rViscumin in blood plasma. "
01/01/2011 - "Mistletoe lectin-I (ML-I), the main anti-cancer component of mistletoe extracts, was originally thought to act exclusively on 28S rRNA. "
08/20/2004 - "rViscumin is a recombinant mistletoe lectin under clinical investigation as new anti-cancer drug. "
08/20/2004 - "Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells."
11/01/2001 - "The results indicate that rViscumin has antineoplastic properties and might therefore be a promising candidate in cancer therapy."
|2.||Melanoma (Melanoma, Malignant)
01/15/2008 - "This study investigates the effects of mistletoe lectin-I (ML-I) on melanoma growth and spread in vivo. "
01/15/2008 - "Mistletoe lectin-I increased apoptosis rates in the melanoma cells of PTs at all doses, while no induction of apoptosis was noted in the LMs. "
01/15/2008 - "Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model."
09/01/2010 - "Mistletoe lectin-I augments antiproliferative effects of the PPARgamma agonist rosiglitazone on human malignant melanoma cells."
09/01/2010 - "For both mistletoe lectin-I (ML-I) and the thiazolidinediones as synthetic ligands of the peroxisome proliferator-activated receptor gamma (PPARgamma) an antiproliferative effect on malignant melanoma cells has previously been shown. "
|3.||Pancreatic Neoplasms (Pancreatic Cancer)
|4.||Neoplasm Metastasis (Metastasis)
04/01/1997 - "Initial clinical trials were promising and currently prospectively randomized multicentre trials are being performed to evaluate the ability of complementary mistletoe lectin-I treatment to reduce the rate of tumor recurrences and metastases, to improve the overall survival as well as the quality of life and to exert immunoprotection in cancer patients under tumor destructive therapy."
01/01/1992 - "Comparative studies on internalization of gold labelled mistletoe lectin I (MLI), its subunits, and of an immunotoxin into mouse L 1210V leukemia cells."
12/10/2002 - "rViscumin enhanced the cytotoxic effects of vincristine, mafosfamide, idarubicin and cisplatin in the human leukemia cell lines K562 and KG1a. "
|1.||Viscum ribosome inactivating protein
|2.||mistletoe lectin I
|8.||Interleukin-1alpha (Interleukin 1 alpha)
|9.||Proteasome Endopeptidase Complex (Proteasome)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)